Results 111 to 120 of about 1,481 (180)

The Association between Intranasal Esketamine and Treatment- emergent Insomnia in the Treatment of Treatment-resistant Major Depression:A Meta-analysis [PDF]

ObjectiveIntranasal (IN) esketamine represents a novel add-on treatment for treatment-resistant depression (TRD) with reported favourable effects on insomnia.
Boesjes, Rutger, Kamphuis, Jeanine, Schoevers, Robert A., Türkmen, Cagdas, van Dalfsen, Jens, Viechtbauer, Wolfgang, Zandbergen, Anne Fleur   +6 more
core   +1 more source

Ketamine cystitis following ketamine therapy for treatment-resistant depression - case report [PDF]

BACKGROUND: Ketamine is a novel and exciting putative antidepressant medication for patients with treatment-resistant depression. A complication commonly seen in frequent and heavy recreational use of ketamine is ulcerative cystitis, which presents with ...
Chang, Minna, Juruena, Mario F, Young, Allan H   +2 more
core   +1 more source

Moving Forward with Ketamine Therapy: Ensuring Safety, Efficacy, and Accessibility in Depression Treatment [PDF]

Ketamine, a medication long used in anesthesia, has emerged as a promising treatment for depression and other mental health disorders. Its rapid onset of action and mechanism, which differs from traditional antidepressants by targeting NMDA receptors ...
DeSanto, Julienne
core   +2 more sources

Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States

Drugs - Real World Outcomes
Background This study aimed to understand treatment patterns, acute healthcare use, and cost patterns among adults with treatment-resistant depression (TRD) who completed induction treatment with esketamine nasal spray in the United States (US).
Lisa Harding, Kruti Joshi, Maryia Zhdanava, Aditi Shah, Arthur Voegel, Cindy Chen, Dominic Pilon   +6 more
doaj   +1 more source

Oral esketamine for difficult-to-treat depression [PDF]

Depressive disorder is a common mental health condition that causes significant personal suffering, functional limitations, loss of productivity, and high healthcare costs.
Smith-Apeldoorn, Sanne
core   +1 more source

Ketamine in Prevention and Treatment of Postpartum Depression - Literature Review [PDF]

Introduction and purpose: Ketamine, used as an anesthetic and analgesic, has gained considerable attention in recent years in the context of treating various psychiatric disorders, particularly the treatment of drug-resistant depression.
Chról, Michał, Dzikowska, Izabela, Gronowicz, Gabriela, Homa, Wojciech, Siejka, Agata, Stefaniak, Daria, Wanat, Joanna, Warunek, Aleksandra, Zielińska, Weronika   +8 more
core   +1 more source

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. [PDF]

CNS Drugs, 2023
Castro M, Wilkinson ST, Al Jurdi RK, Petrillo MP, Zaki N, Borentain S, Fu DJ, Turkoz I, Sun L, Brown B, Cabrera P.   +10 more
europepmc   +1 more source

Esketamine Nasal Spray Improves Rate and Time to Remission Versus Quetiapine Extended Release in Subgroups of Patients With Treatment Resistant Depression and Two or Three Plus Prior Treatment Failures: Results From ESCAPE-TRD, a Randomised Phase IIIb Tri [PDF]

, 2023
Cubala, W. J., Godinov, Y., Ito, T., Mulhern-Haughey, S., Nielsen, R. E., Pirotte, N., Popova, A., Rive, B., Thilakarathne, P., Usankova, I., Young, A. H.   +10 more
core   +2 more sources

Esketamine nasal spray approved for treatment-resistant depression

American Journal of Health-System Pharmacy, 2019
openaire   +2 more sources

Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. [PDF]

Neuropsychopharmacology, 2023
Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, Sanacora G, Wilkinson ST, Popova V, Fu DJ.   +9 more
europepmc   +1 more source